Marfan Syndrome

Marfan Syndrome

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Marfan Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • MFS

Disorder Subdivisions

  • Marfan syndrome type I
  • Marfan syndrome type II

General Discussion

Marfan syndrome is a genetic disorder that affects connective tissue, which is the material between cells of the body that gives the tissues form and strength. Connective tissue is found all over the body and multiple organ systems may be affected in individuals with Marfan syndrome. The heart and blood vessels (cardiovascular), skeletal, and eye (ocular) systems are most often affected. Major symptoms include overgrowth of the long bones of the arms and legs, abnormal side-to-side curvature of the spine (scoliosis), indentation or protrusion of the chest wall (pectus), dislocation of the lenses of the eyes (ectopia lentis), nearsightedness (myopia), widening (aneurysm) and tear (dissection) of the main artery that carries blood away from the heart (aorta), floppiness of the mitral valve (mitral valve prolapse) and backward flow of blood through the aortic and mitral valves (aortic and mitral regurgitation). The specific symptoms and the severity of Marfan syndrome vary greatly from case to case. Marfan syndrome is inherited as an autosomal dominant trait. Defects or disruptions (mutations) of the fibrillin-1 (FBN1) gene have been linked to Marfan syndrome and related disorders.

Symptoms

The specific symptoms of Marfan syndrome vary greatly from case to case. Some individuals will develop only a few mild or isolated symptoms; others will develop more serious complications. In most cases, Marfan syndrome progresses as individuals grow older. In some infants, Marfan syndrome may cause severe, rapidly progressive complications during infancy, often quickly affecting multiple organ systems early in life. Marfan syndrome can potentially affect many systems of the body including the heart, blood vessels, skeleton, eyes, lungs, and skin.



Individuals with Marfan syndrome often develop distinct physical findings especially an abnormally thin physique and disproportionately long, slender arms and legs (dolichostenomelia) due to overgrowth of the long bones. In addition, affected individuals usually have abnormally long, slender fingers (arachnodactyly). People with Marfan syndrome are usually very tall and thin. They can lack muscle tone (hypotonia) and have little fat under the skin (subcutaneous fat).



A variety of skeletal malformations affect individuals with Marfan syndrome including overgrowth of the ribs, which can push the breastbone (sternum) inward resulting in a sunken chest (pectus excavatum) or outward resulting in a protruding chest (pectus carinatum). Additional symptoms include abnormally loose or flexible joints (joint hypermobility), flat feet (pes planus), fingers that are permanently bent or "fixed" and cannot extend or straighten fully (camptodactyly), and reduced extension of the elbow. In some cases, the joints may be unaffected or may become tight and stiff (contractures). Some individuals have an abnormally deep hip socket (acetabulum) with deep insertion of the head of the long bone (femur) of the leg (protrusio acetabulae) and signs of erosion. Many individuals with Marfan syndrome develop spinal abnormalities such as progressive curving of the spine (scoliosis) that may be mild or severe. Scoliosis may be associated with back pain in some cases. In children, skeletal abnormalities may progress during growth.



Individuals with Marfan syndrome may have several distinct facial features including a long, narrow skull (dolichocephaly), deep-set eyes (enophthalmos), an abnormally small jaw (micrognathia) that may be recessed farther back than normal (retrognathia), abnormally flat cheek bones (malar hypoplasia), and an abnormal downward slant to the eyes. Affected individuals may also exhibit a highly-arched roof of the mouth (palate), teeth that are crowded together and upper and lower teeth that do not meet (align) properly when biting (malocclusion).



Individuals with Marfan syndrome may have significant cardiovascular problems such as a common heart defect known as mitral valve prolapse. The mitral valve is located between the left upper and left lower chambers (left atrium and left ventricle, respectively) of the heart. Mitral valve prolapse occurs when one or both of the flaps (cusps) of the mitral valve bulge or collapse backward (prolapse) into the left upper chamber (atrium) of the heart during contraction. In some cases, this may allow leakage or the backward flow of blood from the left lower chamber of the heart (ventricle) back into the left atrium (mitral regurgitation). In some cases, no associated symptoms are apparent (asymptomatic). However, in other cases, mitral valve prolapse can result in chest pain, abnormal heart rhythms (arrhythmias), or evidence of inadequate heart function (congestive heart failure)



Additional cardiovascular symptoms include widening (aneurysm) and degeneration of the main artery that carries blood away from the heart (aorta), tearing (dissection) of the aorta so that blood seeps between the inner and outer layers of the aortic wall, and backward flow of blood from the aorta into the lower left chamber (ventricle) of the heart (aortic regurgitation). Some individuals may develop widening of the main artery of the lungs (pulmonary artery dilatation). If left untreated, the various heart abnormalities potentially associated with Marfan syndrome can cause life-threatening complications such as rupture of the aorta and congestive heart failure.



Individuals with Marfan syndrome develop abnormalities of the eyes, especially nearsightedness (myopia), which may develop early in childhood and become progressively worse. Approximately 60 percent of individuals develop displacement of the lenses of the eyes (ectopia lentis) away from the center of the eyeball. Ectopia lentis may occur at birth or later in life and may remain stable or become progressively worse.



Additional symptoms affecting the eyes include an abnormally flat cornea (the clear portion of the eyes through which light passes), underdevelopment of the colored portion of the eye (hypoplastic iris), and detachment of the nerve-rich membrane (retina) lining the back of the eyes. Individuals with Marfan syndrome are at risk for the early development of cataracts or glaucoma. If left untreated, eye abnormalities can result in vision loss.



In addition to the more common symptoms discussed above, individuals with Marfan syndrome may develop air pockets near the top of the lungs (apical pulmonary blebs), which can predispose individuals to a leak of air within the chest cavity and lung collapse that occurs for no readily apparent reason (spontaneous pneumothorax). In some cases, pneumothorax can recur.



Some affected individuals may develop widening or bulging of the sac (dura) that surrounds the spinal cord (dural ectasia). This condition usually does not cause symptoms (asymptomatic), but has been associated with lower back pain. Affected individuals may also developed stretch marks (stria atrophicae) on certain areas of the skin without an obvious cause. In some cases, affected individuals may have an inguinal, umbilical or surgical hernia, in which a weakened portion of the pelvic or abdominal wall allows external bulging of a small segment of the intestines.



MARFAN SYNDROME TYPE II

Some researchers have identified a subset of individuals with symptoms that are extremely similar to those associated with Marfan syndrome; however, these individuals have a mutation of a different gene (see Causes section below). Some researchers have designated these individuals as having Marfan syndrome type II. Other researchers believe that these individuals have a disorder distinct from and, yet similar to, classic Marfan syndrome (called Loeys-Dietz syndrome). Such individuals may be at risk for more widespread aneurysms throughout the arterial tree and for aneurysms that tear or rupture at earlier ages and smaller dimensions when compared to classic Marfan syndrome. People thought to have Marfan syndrome type II require specialized counseling, imaging protocols and management.

Causes

Marfan syndrome is inherited as an autosomal dominant condition. Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary to cause a particular disease. The abnormal gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. In approximately 25-30 percent of Marfan syndrome cases, this mutation occurs as the result of a new mutation. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy. The risk is the same for males and females.



Marfan syndrome has been linked to defects or disruptions (mutations) of the fibrillin-1 (FBN1) gene. Not everyone who has a mutation of this gene develops the symptoms of Marfan syndrome.



Investigators have determined that most cases (> 95%) of Marfan syndrome occur due to mutation of the FBN1 gene located on the long arm (q) of chromosome 15 (15q21.1). Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes are numbered from 1 through 22 and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated "p" and a long arm designated"q". Chromosomes are further sub-divided into many bands that are numbered. For example,"chromosome 15q21.1" refers to band 21.1 on the long arm of chromosome 15. The numbered bands specify the location of the thousands of genes that are present on each chromosome.



The FBN1 gene contains instructions for developing (encoding) a protein known as fibrillin-1. Fibrillin-1 is a component of structures called microfibrils, which are fiber-like structures that are part of the extracellular matrix, a complex material that surrounds and supports cells throughout the body. Researchers believe fibrillin-1 plays an essential role in giving connective tissue its characteristic elastic-like flexibility and strength. Without fibrillin, connective tissue may be weak.



The so-called Marfan syndrome type II has been linked to mutations of the TGF-beta receptor 2 (TGFBR2) gene located on the short arm (p) of chromosome 3 (3p22). The protein that this gene creates (encodes) serves as a binding site at the cell surface (receptor) for a molecule called transforming growth factor beta (TGFbeta). TGFbeta instructs the behavior of cells. Mutations in the TGFbeta receptor alters TGFbeta activity and cell behavior.

Affected Populations

Marfan syndrome affects males and females in equal numbers and occurs worldwide with no ethnic predisposition. The prevalence has been estimated to be 1 in 5-10,000 individuals in the general population. Because of the difficulty in diagnosing mild cases of Marfan syndrome, the disorder is probably underdiagnosed, making it difficult to determine its true frequency in the general population.

Standard Therapies

Diagnosis

No universal, specific diagnostic test exists for Marfan syndrome despite the identification of the causative gene. A diagnosis is made based upon a detailed patient and family history, a thorough clinical evaluation, and a variety of specialized test performed to identify key findings associated with Marfan syndrome. Different criteria have been proposed for classifying someone as having Marfan syndrome. The most recent published criteria (the revised Ghent nosology) were published in 2010. According to these guidelines, the presence of aortic root aneurysm, eye lens dislocation, or a family history of definite Marfan syndrome weigh heavily in the diagnosis of Marfan syndrome, with an additional potential contribution of other findings throughout the body. Molecular testing (e.g. looking for a mutation in the FBN1 gene) can aid in the diagnosis of Marfan syndrome, but identifying a mutation is not sufficient to establish the diagnosis in the absence of sufficient physical findings.



Individuals suspected of having Marfan syndrome will usually undergo a complete skeletal examination, a heart examination including a test that uses sound waves to produce images of the heart (echocardiogram), and a specialized examination of the eyes (slit-lamp eye examination). A slit-lamp allows an eye doctor to examine the eyes under high magnification to detect lens dislocation and other eye issues. It is essential that this comprehensive diagnostic evaluation be coordinated by someone very familiar with Marfan syndrome and related diagnoses.



Treatment

The treatment of Marfan syndrome is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists including geneticists, surgeons, cardiologists, dental specialists, eye specialists (ophthalmologists), orthopedists, and other healthcare professionals.



Individuals with Marfan syndrome are encouraged to avoid competitive and contact sports, heavy lifting and any exercise that increases the strain on the aorta produced by rapid or vigorous beating of the heart or increased blood pressure. Restriction of such activities can slow the rate of the widening of the aorta (aortic dilatation). In general, moving types of exercises performed in moderation are thought to be good for people with Marfan syndrome. Such exercises, performed regularly, will naturally lower heart rate and blood pressure.



Beta-adrenergic blocking drugs such as propranalol and atenolol are often used in treating the cardiovascular problems associated with Marfan syndrome. Both drugs help to reduce the strength and frequency of the contractions of the heart. In doing so, they may reduce the strain on the walls of the aorta. Beta-blockers generally produce few side effects and may delay the need for heart surgery. The dosage needs to be adjusted to the individual patients needs, and therapy should be closely monitored. Some individuals may not be able to tolerate these drugs and others such as those with asthma may not be able to take them (contraindicated).



Every person with Marfan syndrome should have at least a yearly echocardiogram to check the size and function of the heart and aorta. Surgical repair of the aorta may eventually become necessary if the aorta has severely widened or developed a tear (dissection). Preventive (prophylactic) surgery is recommended when the diameter of the aorta reaches 5 centimeters in older children or adults, when the rate of widening reaches 1 centimeter a year, or when there is severe or progressive backflow (regurgitation) of blood through the aortic valve. Surgery may also be necessary for leakage of the mitral valve. Replacement of the aortic valve may be performed; however, this surgery requires the lifelong use of medications to prevent blood clots (anticoagulation). In recent years, some physicians have preferred to use valve-sparing surgery (i.e., reimplantation or remodeling of the aortic valve). Studies are underway to assess the durability of valve-sparing procedures.



Surgery to repair or replace the mitral valve in individuals who experience severe mitral valve regurgitation may become necessary as well. Cardiovascular problems related to Marfan syndrome increase affected individuals' susceptibility to repeated bacterial infections such as infections of the heart valves (bacterial endocarditis). Leaking heart valves are more prone to infection with bacteria. While it had been common practice to treat patients with leaking valves with antibiotics before dental work or other procedures expected to contaminate the blood stream with bacteria, the American Heart Association recently withdrew this recommendation for most people. Given the predisposition of people with Marfan syndrome and other connective tissue disorders to progressive leakage through multiple heart valves, many physicians who routinely care for such individuals continue to recommend that antibiotics be used.



Skeletal abnormalities such as scoliosis and deformity of the chest may represent serious problems for people with Marfan syndrome. Braces may be tried to correct skeletal curving (scoliosis) in some cases, but can be ineffective. Individuals with curvature of the spine of more than 10 degrees should be followed by an orthopedist. Surgical stabilization of the spine may be needed if the curvature is severe or progressive. A sunken chest (pectus excavatum) may be surgically corrected for cosmetic reason or, in rare severe cases, to avoid medical complications.



The eyes require careful attention (e.g., yearly ophthalmologic exams) from early childhood. Failure to detect any of the several abnormalities that can affect the eyes may result in poor vision and other visual impairment. Increased risk of retinal detachment does demand special attention. The eyes should receive special protection from injury during work or sports. Sports that may involve trauma to the head, such as football, boxing, and diving, should be avoided. Displacement of the lenses may be treated with eyeglasses or contact lenses. Some individuals such as those with a completely loose lens or with a displaced lens that disrupts vision may require surgical intervention. A detached retina may also be corrected through surgical reattachment.



Genetic counseling may be of benefit for affected individuals and their families. Other treatment is symptomatic and supportive.

Investigational Therapies

Researchers are studying a variety of drugs including calcium channel blockers (such as verapamil), ACE inhibitors, and angiotensin receptor blockers (ARBs) such as losartan as potential alternatives to therapy with beta-blockers. More research is necessary to determine the long-term safety and effectiveness of these potential therapies for individuals with Marfan syndrome.



Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com



Contact for additional information about Marfan syndrome:



Hal Dietz, MD

Victor A. McKusick Professor of Medicine and Genetics

Investigator, Howard Hughes Medical Institute

Institute of Genetic Medicine

Departments of Pediatrics, Medicine, and Molecular Biology & Genetics

Johns Hopkins University School of Medicine

733 N. Broadway, BRB 539

Baltimore, MD 21205

(410) 614-0701

(410) 614-2256 (fax)

hdietz@jhmi.edu

References

TEXTBOOKS

Dietz H. Marfan Syndrome. NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:218-9.



Berkow R., ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:1608-9.



Jones KL. Ed. Smith's Recognizable Patterns of Human Malformation. 5th ed. W. B. Saunders Co., Philadelphia, PA; 1997:546.



JOURNAL ARTICLES

Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47:476-485.



Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet. 2007;15:274-33.



Forteza A, Cortina JM, Sanchez V, et al. Aortic valve preservation in Marfan syndrome. Initial experience. Rev Esp Cardiol. 2007;60:471-5.



Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev. 2007;17:252-8.



Judge DP, Deitz HC. Marfan's syndrome. Lancet. 2005;366:1965-76.



Gott VL, Cameron DE, Alejo DE, et al. Aortic root replacement in 271 Marfan patients: a 24-year experience. Ann Thorac Surg. 2002;73:438-43.



Le Parc JM, Molcard S Tubach F, et al. Marfan syndrome and fibrillin disorders. Joint Bone Surg. 2000;67:401-7.



Collod G, Babron M-C, Jondeau G, et al. A second locus for Marfan syndrome maps to chromosome 3p24.2-p25. Nat Genet. 1994;8:264-8.



Dietz HC, Pyeritz RE, Hall BD, et al. The Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-9.



Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol. 1986;103:2499-509.



FROM THE INTERNET

Chen H. Marfan syndrome. Emedicine Journal. http://www.emedicine.com/ped/topic1372.htm. Updated March 10, 2010. Accessed June 8, 2011.



Channell K. Marfan syndrome. Emedicine Journal http://www.emedicine.com/orthoped/topic414.htm. Updated April 9, 2010. Accessed June 8, 2011.



Dietz HC. Updated 6/30/2009. Marfan Syndrome. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2003. Available at http://www.genetests.org. Accessed 6/8/2011.



Le Parc J-M. Marfan syndrome. Orphanet encyclopedia, February 2005. Available at: http://www.orpha.net/data/patho/GB/Marfan-interm.htm. Accessed June 8, 2011.



Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Marfan Syndrome; MFS. Entry No: 154700. Last Edited January 14, 2011. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed June 8, 2011.



Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Loeys-Dietz Syndrome, Type 2B; LDS2B (Marfan Syndrome, Type II, Formerly). Entry No: 610380. Last Updated July 6, 2010. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed June 8, 2011.

Resources

National Scoliosis Foundation

5 Cabot Place

Stoughton, MA 02072

Tel: (781)341-8333

Fax: (781)341-8333

Tel: (800)673-6922

Email: nsf@scoliosis.org

Internet: http://www.scoliosis.org



National Marfan Foundation

22 Manhasset Avenue

Port Washington, NY 11050

Tel: (516)883-8712

Fax: (516)883-8040

Tel: (800)862-7326

Email: staff@marfan.org

Internet: http://www.marfan.org



American Heart Association

7272 Greenville Avenue

Dallas, TX 75231

Tel: (214)784-7212

Fax: (214)784-1307

Tel: (800)242-8721

Email: Review.personal.info@heart.org

Internet: http://www.heart.org



NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Information Clearinghouse

One AMS Circle

Bethesda, MD 20892-3675

USA

Tel: (301)495-4484

Fax: (301)718-6366

Tel: (877)226-4267

TDD: (301)565-2966

Email: NIAMSinfo@mail.nih.gov

Internet: http://www.niams.nih.gov/



Coalition for Heritable Disorders of Connective Tissue (CHDCT)

4301 Connecticut Avenue, NW Suite 404

Washington, DC 20008

Tel: (202)362-9599

Fax: (202)966-8553

Tel: (800)778-7171

Email: chdct@pxe.org

Internet: http://www.chdct2.org/



Canadian Marfan Association

Centre Plaza Postal Outlet

128 Queen Street South

P.O. Box 42257

Mississauga

Ontario, L5M 4Z0

Canada

Tel: 9058263223

Fax: 9058262125

Tel: 8667221722

Email: info@marfan.ca

Internet: http://www.marfan.ca



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org



Cleft Lip and Palate Foundation of Smiles

2044 Michael Ave SW

Wyoming, MI 49509

Tel: (616)329-1335

Email: Rachelmancuso09@comcast.net

Internet: http://www.cleftsmile.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.